Oncolytic Virus Manufacturing

Virus manufacturing for oncolytic therapies

ABL has increased capacity, increased scale, and diversified capabilities to offer a variety of suspension and adherent production platforms to manufacture our clients’ novel oncolytic therapies.

Global capabilities include:

  • Oncolytic viral vector manufacturing — adherent & suspension platforms:
    • Vaccinia
    • MVA
    • HSV
    • Adenovirus
    • Others
  • Aseptic processing for drug substance & drug product
  • US- & EU-based GMP operations
  • Global supply for Phase I – III & product approval
  • Comprehensive QC release & stability testing
  • Process & analytical development, qualification, characterization & validation
  • 10+ years proven technical & regulatory track record in oncolytic virotherapies
oncolytic virus manufacturing

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

 

ABL, Inc. (ABL), a global contract manufacturing organization that advances leading vaccines and therapies from clinical development to the commercial market, is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe SAS (ABL Europe), of a 6,500 m2 GMP manufacturing site located in Lyon, France.

Contact us now to speak with one of our experts: